Inovio Pharmaceuticals Inc (INO)

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines for diseases linked to human papillomavirus (HPV), cancer, and infectious diseases. Its platform combines SynCon technology for designing plasmid DNA and CELLECTRA delivery devices to administer those plasmids. The company’s lead candidate is INO-3107, which is being studied in Phase 1/2 development for HPV-related recurrent respiratory papillomatosis. Other pipeline programs include VGX-3100 for HPV-related cervical high-grade squamous intraepithelial lesions, INO-3112 for HPV-related oropharyngeal squamous cell carcinoma, INO-5401 for glioblastoma multiforme, INO-4201 for Ebola virus disease, INO-4800 for COVID-19, and INO-6160 for HIV, with development stages ranging from Phase 1 to Phase 2/3. Inovio was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania. The company also works with a range of collaborators, including ApolloBio Corporation, AstraZeneca, Coherus Biosciences, DARPA, the HIV Vaccines Trial Network, Kaneka Eurogentec, the NIH, NIAID, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and the Wistar Institute.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.